AGP Executive Report

Wealthtech & cross-border banking: Objectway is buying FNZ Switzerland’s private banking technology business (formerly New Access), adding 160+ staff and tech used by 40+ private banks, and strengthening its core-to-digital platform for Liechtenstein and Switzerland-based wealth managers. Crypto regulation in the EU/EEA: ESMA expanded its MiCA register by 37 newly authorized crypto-asset service providers, lifting the total to 280 after the July 1 transition deadline; Liechtenstein is listed among regulators with one new authorization. Trade & market access: EFTA and Vietnam concluded a long-running free trade agreement, with Liechtenstein included among the EFTA states that will see reduced barriers and broader coverage for services, investment, and procurement. Pharma for Liechtenstein patients: SERB Pharmaceuticals completed rights acquisition for Idefirix (imlifidase) across the EU plus Switzerland and Liechtenstein, positioning the therapy for wider availability after an EMA post-authorization step. Digital payments: Visa launched live AI-agent payments across Europe with participating Swiss issuers, using passkey-based authorization and a trusted-agent framework.

MiCA enforcement hits full stride: ESMA updated its MiCA register with 37 newly licensed crypto-asset service providers, lifting the EU total to 280 after the July 1 transition deadline. Liechtenstein in the mix: The latest batch includes one authorization each for Germany, Liechtenstein, and Latvia, while Cyprus led with six new approvals. Banking meets crypto: Standard Chartered secured MiCA authorization via its Luxembourg unit, positioning it as a regulated entry point for digital-asset services across the EU. Trade ties expand for EFTA: EFTA and Vietnam concluded a long-running free trade agreement, with Liechtenstein among the four EFTA states set to gain improved market access once ratified. Healthcare industry milestone: CinnaGen’s teriparatide biosimilar Zandoriah® received European Commission marketing authorization, covering EU27 plus Iceland, Liechtenstein, and Norway. Wealthtech deal with local impact: Objectway agreed to acquire FNZ’s Swiss private banking technology business, strengthening its presence in Switzerland and Liechtenstein.

MiCA Enforcement Hits Home: ESMA updated its MiCA register with 37 newly licensed crypto-asset service providers, lifting the EU total to 280 after the July 1 transition deadline. Cyprus led the batch with six approvals, while Liechtenstein recorded one. Liechtenstein Finance Growth: Sygnum Europe is scaling EU access after securing a CASP licence for its Liechtenstein subsidiary, positioning the firm to serve EU/EEA clients under MiCAR. Wealthtech Deal in the Region: Objectway agreed to acquire FNZ’s Swiss private banking technology business (New Access), adding 160+ employees and expanding its core-to-digital platform across Switzerland and Liechtenstein. EFTA Trade Push: EFTA and Vietnam concluded free trade agreement talks, with Liechtenstein among the four EFTA states set to gain improved market access once ratified. Life Sciences Expansion: The European Commission authorized CinnaGen’s Zandoriah® (teriparatide) for EU-wide marketing, including Liechtenstein and Norway, supporting broader osteoporosis access. Travel Friction Watch: Europe’s Entry/Exit System (EES) is driving calls for urgent border-delay fixes as summer queues grow, affecting Schengen travel planning.

MiCA Enforcement Hits Liechtenstein-Linked Finance: ESMA updated its MiCA register with 37 new licensed crypto-asset service providers after the July 1 transition deadline, lifting EU totals to 280 (from 243). Notable entrants include Standard Chartered (via Luxembourg) and FalconX (Malta), with Cyprus leading the latest batch; Liechtenstein appears among the countries with new authorizations. Cross-Border Wealth Tech Deal: Objectway agreed to acquire FNZ Switzerland’s private banking technology business (formerly New Access), adding 160+ employees and tech used by 40+ private banks, and explicitly strengthening its footprint in Switzerland and Liechtenstein. EFTA-Vietnam Trade Breakthrough: EFTA and Vietnam concluded a long-running free trade agreement, covering goods and services, investment, IP, procurement, and sustainable development—opening a new chapter for Liechtenstein’s EFTA-linked trade ties. EU Pharma Expansion for Liechtenstein Access: The European Commission authorized CinnaGen’s Zandoriah® (teriparatide) for EU27 plus Iceland, Liechtenstein, and Norway, supporting broader launch planning across Europe. Payments Innovation: Visa launched live AI-agent payment trials across Europe, using trusted-agent protocols and passkey authentication—relevant for Liechtenstein’s banking and fintech ecosystem. Border Friction Watch: The EU Entry/Exit System (EES) is still triggering summer delays and calls for urgent fixes, with Liechtenstein included in the Schengen EES coverage.

Objectway Expansion in Wealth Tech: Objectway agreed to buy FNZ Switzerland’s Swiss private banking technology business (formerly New Access), adding 160+ employees and tech used by 40+ private banks, and strengthening its core-to-digital platform for cross-border wealth management across Switzerland and Liechtenstein. EFTA–Vietnam Trade Deal: EFTA ministers concluded a long-running free trade agreement with Vietnam, paving the way for lower barriers and broader coverage including services, investment, IP, procurement and sustainable development—important for Liechtenstein-linked trade flows. MiCAR Aftershock for Crypto: With the MiCA transition ending July 1, reporting suggests most European crypto providers may lose authorization, driving migration toward lighter-touch hubs like Dubai; Liechtenstein’s MiCAR licensing is positioned as a compliance route for EU access. Border Tech Pressure on Travel: The EU’s Entry/Exit System (EES) is still triggering major summer delays at Schengen borders, with airlines and airports urging fixes to protect tourism and connectivity. Healthcare Innovation with Liechtenstein Reach: SERB Pharmaceuticals completed rights acquisition for Idefirix (imlifidase) covering EU/UK/Switzerland and Liechtenstein, aiming to expand availability for rare transplant-related use.

Crypto Infrastructure: Bitcoin Suisse says it’s migrating its Ethereum staking validators to Obol Distributed Validators, moving from single-validator setups to a more resilient distributed standard after a year of production use. Trade & Market Access: EFTA and Vietnam sign a “modern and comprehensive” free trade agreement covering goods/services, rules of origin, SPS, technical barriers, investment, IP, and public procurement, with Switzerland represented by President Parmelin. Schengen Border Tech: Europe’s Entry/Exit System (EES) is driving major summer travel delays, with biometric registration for non-EU short-stay visitors (including Liechtenstein and Switzerland) and calls from airports/airlines for urgent fixes. Aviation Compliance: Delta confirms ETIAS pre-travel authorization for visa-exempt non-EU travelers starting late 2026, with a fee for trips to many European destinations. Finance & Regulation: MiCA’s July 1 deadline is triggering a scramble—only a fraction of crypto firms have licenses, and many are reportedly looking to relocate to Dubai. Wealthtech in Liechtenstein: Objectway acquires FNZ’s Swiss private banking technology business, expanding its private-banking footprint across Switzerland and Liechtenstein. Healthcare & Biotech: SERB completes acquisition of EU/UK/CH/NO/LI rights to Idefirix (imlifidase), while Acadia’s DAYBU (trofinetide) gets a positive CHMP opinion for Rett syndrome in the EU.

Heat & Cooling: Europe’s 2003 heatwave killed 20,000+ and records are being broken again this year, yet only ~20% of Europeans have air conditioning versus ~90% in the US—raising pressure on hospitals, schools, and outdoor work planning. Border Tech & Travel Ops: The EU Entry/Exit System (EES) is driving queues and calls to pause it during peak summer, with Schengen countries (including Liechtenstein) using biometrics for non-EU travellers and airports warning of major disruption. Crypto Regulation Shift: With MiCA’s July 1 deadline, the EU/EEA is set to squeeze out unauthorized crypto firms; only 244 of 3,000+ registered providers reportedly secured licenses, pushing migration toward lighter-touch hubs like Dubai. Liechtenstein in Finance: Sygnum says its Liechtenstein-based CASP licence under MiCAR gives it direct EU access as it scales EU operations. Pharma Pipeline: SERB completed rights acquisition for Idefirix® (imlifidase) covering EU/UK/Switzerland and Liechtenstein, while Neuren’s DAYBU (trofinetide) gained a positive CHMP opinion for Rett syndrome in the EU. Trade & Industry: The EU moves to cut steel imports via a tariff-free quota system, while the UK consolidates dual-use export licensing into a new OGEL to reduce paperwork. AI in Finance: Research warns that widespread AI trading could crowd markets, shorten signal lifespans, and increase systemic risk.

MiCA Shockwave for Crypto: With the MiCA transition ending July 1, EU/EEA access is tightening fast—only 244 of 3,000+ prior registrants reportedly secured licenses, and OKX’s CEO expects up to 80% of firms to exit. Liechtenstein as a Gateway: Sygnum is scaling EU access via a Liechtenstein-based CASP/MiCAR setup, positioning the principality as a regulated bridge into the bloc. Cross-Border Travel Friction: Europe’s new Entry/Exit System (EES) is driving fresh airport warnings about summer border delays, and families are being told to prepare for child biometrics and longer queues. Private Banking Tech Moves: Objectway is buying FNZ’s Swiss private banking technology unit, expanding its footprint across Switzerland and Liechtenstein. Healthcare & Pharma Uptick: SERB completed rights acquisition for Idefirix (imlifidase) covering EU/UK/Switzerland and Liechtenstein, while Merck won EU approval for Keytruda+Padcev in cisplatin-ineligible bladder cancer and Neuren’s DAYBU gained a positive CHMP opinion for Rett syndrome. Trade Pressure on Industry: The EU is preparing steel import quota changes tied to “alliance” partners, and Brussels is weighing anti-subsidy tariffs on Chinese plug-in hybrids.

MiCA Deadline Shock for Crypto: With July 1 ending the EU transition, Liechtenstein-licensed crypto firms are moving into full operating mode while many unlicensed providers face a squeeze; Sygnum Europe says its Liechtenstein CASP licence now gives it direct EU/EEA access for private wealth and institutions, as the broader market braces for major contraction. EU Trade Protection for Industry: Brussels is preparing tariff-free steel import quotas that favor existing free-trade partners, while also weighing wider tariff moves that could hit Chinese plug-in hybrid growth. Healthcare Innovation in the EU/EEA: The EU has approved Merck’s perioperative KEYTRUDA plus Padcev regimen for cisplatin-ineligible muscle-invasive bladder cancer, extending a new option across EU states plus Iceland, Liechtenstein and Norway. Cross-Border Compliance & Mobility: The EU’s Entry/Exit System is rolling out for non-EU travelers to Schengen, with Liechtenstein included, meaning more biometric processing at borders this summer. Finance & Risk Management: OpenPayd secured MiCA authorization to offer regulated crypto services across the EEA, signaling how quickly regulated infrastructure is becoming the new baseline.

MiCA Push for Liechtenstein Finance: Sygnum Europe (licensed in Liechtenstein) is moving into full EU/EEA operating mode after its CASP authorisation, using its Swiss/Singapore banking platform to expand access for private wealth and institutions as the July 1 MiCA deadline ends the transition. Crypto Compliance Deadline Pressure: With MiCA set to cut off unauthorised crypto providers, firms are scrambling for licences; estimates suggest only a fraction of Europe’s registered providers will make it through, while some are already looking to the UAE for faster market entry. EU Trade Shield for Industry: The European Commission is proposing tariff-free steel import quotas to protect the metals sector, with higher duties for over-quota volumes and allocation rules favoring existing free-trade partners. Cross-Border Healthcare Clarity: A practical guide explains how EU cross-border healthcare works, including when prior authorisation applies and how costs are handled—relevant for Liechtenstein residents traveling for treatment. EU Approves New Bladder Cancer Regimen: The EU has approved Merck’s KEYTRUDA plus Padcev perioperative treatment for cisplatin-ineligible muscle-invasive bladder cancer, extending options across EU member states plus Iceland, Liechtenstein and Norway.

MiCA Push in Liechtenstein Finance: Sygnum says its Liechtenstein-based unit has secured a MiCA licence, giving it direct access to EU and EEA clients as the July 1 transition deadline nears. The firm is positioning its bank-to-bank infrastructure, custody and digital asset products for private wealth and institutions. MiCA Deadline Shock: Separate coverage warns that MiCA’s end of transition could squeeze out most crypto providers: only 244 of 3,000+ prior registrants reportedly completed authorisation, with compliance costs potentially reaching hundreds of thousands of euros. New MiCA Licences Across Europe: OpenPayd also won MiCA authorisation for EEA-wide stablecoin and custody services, while Bitcoin Suisse (Europe) received a MiCAR licence from Liechtenstein’s Financial Market Authority to expand trading, custody and staking. Cross-Border Healthcare Basics: A practical explainer breaks down how EU cross-border care works, including when prior authorisation applies and how costs are handled. EU Border Tech for Summer Travel: The Entry/Exit System (EES) is rolling out for non-EU travellers to Schengen, with biometrics replacing passport stamping and longer waits expected at peak times. EU Approvals for Cancer Care: The EU approved KEYTRUDA plus Padcev for cisplatin-ineligible muscle-invasive bladder cancer, and Trodelvy for first-line metastatic triple-negative breast cancer in eligible patients.

MiCA Deadline Shock: With the July 1 transition ending, Europe’s MiCA rules are set to squeeze out most crypto firms—only 244 of 3,000+ earlier registrants reportedly secured licenses, and compliance costs can hit hundreds of thousands of euros. Liechtenstein Crypto Boost: Bitcoin Suisse (Europe) AG received a MiCAR Crypto Asset Service Provider license from Liechtenstein’s FMA, giving it a regulated base for EEA trading, custody and staking expansion. Payments Infrastructure: OpenPayd also secured MiCA authorization, enabling regulated fiat-to-stablecoin conversions, custody and stablecoin transfers across the EEA via a single license. EU Health Approvals: CHMP backed DAYBU (trofinetide) for Rett syndrome symptoms, and the EU approved perioperative KEYTRUDA plus Padcev for cisplatin-ineligible muscle-invasive bladder cancer. Energy Transition Watch: Offshore wind is being positioned as Asia’s next big investment frontier, with the Philippines highlighted for its coastal wind potential. Travel Rules for the Region: The EU’s Entry/Exit System (EES) will replace passport stamping for non-EU travelers, with Liechtenstein included in the Schengen coverage.

Crypto Regulation in Liechtenstein: Bitcoin Suisse (Europe) AG received a MiCAR Crypto Asset Service Provider license from Liechtenstein’s FMA, giving it a regulated base to serve selected EEA markets with trading, custody and staking. EU Financial Services: OpenPayd also secured MiCA authorization, enabling regulated fiat-to-stablecoin conversions, custody and stablecoin transfers across the EEA via a single API. Healthcare & Pharma (EU-wide, incl. Liechtenstein): Merck won EU approval for KEYTRUDA + Padcev as perioperative treatment for cisplatin-ineligible adults with resectable muscle-invasive bladder cancer, and Gilead’s Trodelvy gained EU marketing authorization for first-line metastatic TNBC ineligible for PD-1/PD-L1 therapy (also covering Norway, Iceland and Liechtenstein). Energy Transition: Offshore wind is being positioned as Asia’s next investment frontier, with the Philippines highlighted for its coastal wind potential and energy-security push. Local Industry & Trade: Liechtenstein Post’s role featured in the Macao 2026 stamp exhibition opening, underscoring how small-country craftsmanship still reaches global audiences.

Water Infrastructure Watch: A new global map highlights that over 2 billion people still lack safely managed drinking water, with access near-universal in parts of Europe and North America but below 20% in several low-income countries, underscoring ongoing pressure for water-system upgrades. Liechtenstein Finance & Crypto Regulation: Bitcoin Suisse (Europe) AG received a MiCAR Crypto Asset Service Provider license from Liechtenstein’s FMA, giving it a regulated base to expand crypto trading, custody and staking across selected EEA markets. EU Pharma Approvals (Liechtenstein included): The European Commission approved KEYTRUDA + Padcev as a perioperative option for cisplatin-ineligible resectable muscle-invasive bladder cancer, and DAYBU (trofinetide) gained a positive CHMP opinion for Rett syndrome neurobehavioral symptoms—both relevant for Liechtenstein patients via EU-wide authorization. Offshore Wind Investment: A report points to the Philippines emerging as an offshore wind investment frontier, driven by energy security and high coastal wind potential. Cross-border Legal Risk: An Ontario court ruling allowed fraud claims to proceed against a Liechtenstein-based trustee, reinforcing how cross-border disputes can hinge on where money was taken.

Liechtenstein Trust in Spotlight: A new UK investigation claims Oxford accepted donations tied to Max Mosley’s fortune, including allegations that the money flowed through a secretive Liechtenstein trust—raising fresh questions about how offshore structures can mask controversial origins. EU Pharma Approvals: The EU is moving forward with new cancer and rare-disease treatments that also cover Liechtenstein: Merck’s perioperative KEYTRUDA plus Padcev regimen for cisplatin-ineligible muscle-invasive bladder cancer, and Gilead’s Trodelvy first-line metastatic triple-negative breast cancer approval; separately, Acadia’s DAYBU (trofinetide) received a positive CHMP opinion for Rett syndrome. Crypto Regulation, Liechtenstein Included: Bitcoin Suisse (Europe) AG secured a MiCAR CASP license from Liechtenstein’s FMA, while OpenPayd also obtained MiCA authorization to expand regulated stablecoin services across the EEA. Cross-Border Finance & Courts: An Ontario court cleared fraud claims to proceed against a Liechtenstein-based trustee in a Bridging Finance dispute, focusing on whether Ontario has jurisdiction over alleged misappropriation. Industry & Energy: The Philippines is being pitched as an offshore wind investment frontier, and Liechtenstein Post highlighted its stamp culture at Macao 2026’s “Stamp Day.”

EMA Watch: Acadia’s DAYBU® (trofinetide) cleared a CHMP positive opinion for marketing authorization in the EU for neurobehavioral symptoms of Rett syndrome in adults and children aged five and up, with the European Commission decision still pending. EU Oncology: Merck’s KEYTRUDA + Padcev perioperative regimen won EU approval for adults with resectable muscle-invasive bladder cancer who can’t receive cisplatin, extending across all 27 EU states plus Iceland, Liechtenstein and Norway. Liechtenstein Finance & Crypto: Bitcoin Suisse (Europe) AG received a MiCAR Crypto Asset Service Provider license from Liechtenstein’s FMA, giving it a regulated base to expand crypto trading, custody and staking across selected EEA markets. Cross-border Lending: An Ontario court allowed fraud claims to proceed against a Liechtenstein-based trustee, ruling the dispute has a real and substantial connection to Ontario. Energy & Industry Context: A report highlights offshore wind as a growing investment target for the Philippines, driven by energy security and long-term cost advantages. Trade & Mobility: New EU border rules via the Entry Exit System (EES) may slow Schengen arrivals for non-EU travelers, including those entering via Liechtenstein.